MX2022011242A - Inmunomodulación de o-het/aril azálidos. - Google Patents

Inmunomodulación de o-het/aril azálidos.

Info

Publication number
MX2022011242A
MX2022011242A MX2022011242A MX2022011242A MX2022011242A MX 2022011242 A MX2022011242 A MX 2022011242A MX 2022011242 A MX2022011242 A MX 2022011242A MX 2022011242 A MX2022011242 A MX 2022011242A MX 2022011242 A MX2022011242 A MX 2022011242A
Authority
MX
Mexico
Prior art keywords
sup
immunomodulating
formula
pharmaceutically acceptable
azalides
Prior art date
Application number
MX2022011242A
Other languages
English (en)
Inventor
Tomasz Respondek
Matthew W Bedore
Richard Andrew Ewin
Susan M K Sheehan
Mark R Cox
Imelda Hot
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of MX2022011242A publication Critical patent/MX2022011242A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

En la presente se definen compuestos inmunomoduladores de la Fórmula (1) estereoisómeros de este y sales farmacéuticamente aceptables de este; en donde R0, R1, R2, R10, W, el anillo C y n son como se define en la presente, estereoisómeros de estos y sales farmacéuticamente aceptables de estos; y composiciones que comprenden dichos compuestos; la invención también incluye métodos para tratar una enfermedad o trastorno inflamatorio y/o inmunológico en un animal al administrar una cantidad terapéuticamente eficaz de un compuesto de la Fórmula (1), estereoisómero de este, y una sal farmacéuticamente aceptable de este; o el uso de dicho compuesto de la Fórmula (1) para preparar un medicamento para tratar una enfermedad o trastorno inflamatorio y/o inmunológico en un animal.
MX2022011242A 2020-03-12 2021-03-11 Inmunomodulación de o-het/aril azálidos. MX2022011242A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062988492P 2020-03-12 2020-03-12
PCT/US2021/021906 WO2021183762A1 (en) 2020-03-12 2021-03-11 Immunomodulating o-het-aryl azalides

Publications (1)

Publication Number Publication Date
MX2022011242A true MX2022011242A (es) 2022-12-15

Family

ID=75278424

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022011242A MX2022011242A (es) 2020-03-12 2021-03-11 Inmunomodulación de o-het/aril azálidos.
MX2022011240A MX2022011240A (es) 2020-03-12 2021-03-11 Azálidos de urea inmunomoduladores.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022011240A MX2022011240A (es) 2020-03-12 2021-03-11 Azálidos de urea inmunomoduladores.

Country Status (11)

Country Link
US (5) US11771677B2 (es)
EP (2) EP4118092A1 (es)
JP (2) JP2023517673A (es)
KR (1) KR20220156570A (es)
CN (2) CN115461352A (es)
AR (1) AR121554A1 (es)
AU (2) AU2021233895A1 (es)
BR (2) BR112022017015A2 (es)
CA (2) CA3175087A1 (es)
MX (2) MX2022011242A (es)
WO (4) WO2021183762A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022343476A1 (en) 2021-09-07 2024-03-21 Zoetis Services Llc Immunomodulating azalides

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0017013B8 (pt) 2000-01-27 2022-11-16 Pfizer Prod Inc composição de antibiótico azalídeo e método para sua obtenção
ITMI20040124A1 (it) * 2004-01-29 2004-04-29 Zambon Spa Macrolidi ad attivita' antiinfiammatoria
JP5126685B2 (ja) * 2006-05-01 2013-01-23 大正製薬株式会社 マクロライド誘導体
EP2188281A1 (en) * 2007-08-10 2010-05-26 Y's Therapeutics Co, Ltd. Modulation of immune responses by administration of roxithromycin or its derivative
US20110039795A1 (en) * 2008-04-23 2011-02-17 Mirjana Bukvic-Krajacic 2'-o,3'-n-bridged macrolides
US20130045939A1 (en) 2010-03-19 2013-02-21 Catabasis Pharmaceuticals, Inc. Fatty acid macrolide derivatives and their uses
CA2869461A1 (en) * 2012-03-27 2013-10-03 Michael W. BURNET Anti-inflammatory macrolides
EP2984087A1 (en) 2013-04-10 2016-02-17 Probiotic Pharmaceuticals APS Azithromycin antimicrobial derivatives with non-antibiotic pharmaceutical effect
GB201608236D0 (en) * 2016-05-11 2016-06-22 Fidelta D O O Seco macrolide compounds

Also Published As

Publication number Publication date
EP4118091A1 (en) 2023-01-18
JP2023517674A (ja) 2023-04-26
US11771677B2 (en) 2023-10-03
CA3175114A1 (en) 2021-09-16
EP4118092A1 (en) 2023-01-18
JP2023517673A (ja) 2023-04-26
CN115461352A (zh) 2022-12-09
AU2021232959A1 (en) 2022-09-15
US20210290591A1 (en) 2021-09-23
AU2021232959B2 (en) 2023-09-07
BR112022017779A2 (pt) 2022-11-29
AR121554A1 (es) 2022-06-15
TW202200158A (zh) 2022-01-01
MX2022011240A (es) 2022-12-15
KR20220156570A (ko) 2022-11-25
CA3175087A1 (en) 2021-09-16
CN115461353A (zh) 2022-12-09
WO2021183759A1 (en) 2021-09-16
BR112022017015A2 (pt) 2022-11-16
WO2021183762A1 (en) 2021-09-16
WO2021183754A1 (en) 2021-09-16
US20230136177A1 (en) 2023-05-04
AU2021233895A1 (en) 2022-09-29
US20230390237A1 (en) 2023-12-07
US20230137567A1 (en) 2023-05-04
US20230129438A1 (en) 2023-04-27
WO2021183758A1 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
MX2021008358A (es) Lipidos para la administracion de agentes activos en nanoparticulas lipidicas.
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
MX2022008066A (es) Compuestos triciclicos sustituidos.
MX2021013472A (es) Moduladores de thr-? y metodos de uso de estos.
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
MX2023007192A (es) Inhibidores de prmt5.
EP4306523A3 (en) Imidazoquinoline compounds and uses thereof
BR0314126A (pt) Ligandos de amida acìclica e sulfonamida para o receptor de estrogênio
MX2010007374A (es) Nuevos derivados de c-21-ceto lupano, preparacion y uso de los mismos.
MX2021011606A (es) Compuestos dirigidos a prmt5.
RU2007138582A (ru) Пероральные дозированные формы производных гемцитабина
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
CR20210513A (es) Compuestos de haxahidro 1-h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
EA202092253A1 (ru) Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5
CO2022008616A2 (es) Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma
MX2021011144A (es) Derivados de las benzodiazepinas como inhibidores del vsr.
MX2022011242A (es) Inmunomodulación de o-het/aril azálidos.
CR20200619A (es) Compuestos de cianotriazol y usos de los mismos
MX2022007171A (es) Compuestos cíclicos y métodos de uso de estos.
CR20190545A (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
WO2020251871A3 (en) Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
PH12020551620A1 (en) Compositions for preventing or treating dry eye